{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:50:59Z","timestamp":1769219459370,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016170","name":"Japan Blood Products Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016240","name":"Nihon Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018046","name":"Nippon Kayaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bbrc.2022.08.010","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T11:41:10Z","timestamp":1660131670000},"page":"156-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells"],"prefix":"10.1016","volume":"626","author":[{"given":"Ryosuke","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Luis","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-525X","authenticated-orcid":false,"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Hanamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.08.010_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10799893.2011.625425","article-title":"Receptor tyrosine kinases: from biology to pathology","volume":"31","author":"Choura","year":"2011","journal-title":"J.\u00a0Recept. Signal Transduct. Res."},{"key":"10.1016\/j.bbrc.2022.08.010_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-pharmtox-011112-140341","article-title":"Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance","volume":"53","author":"Levitzki","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbrc.2022.08.010_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2022.08.010_bib4","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3390\/ijms19113491","article-title":"Receptor tyrosine kinase-targeted cancer therapy","volume":"19","author":"Yamaoka","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2022.08.010_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2022.08.010_bib6","first-page":"S1044","article-title":"EGFR signaling pathway as therapeutic target in human cancers","author":"Levantini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2022.08.010_bib7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2022.08.010_bib8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.08.010_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.08.010_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.08.010_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CLC.2009.n.039","article-title":"Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway","volume":"10","author":"Nguyen","year":"2009","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbrc.2022.08.010_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.resinv.2014.10.002","article-title":"Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance","volume":"52","author":"Takeuchi","year":"2014","journal-title":"Respir. Investig."},{"key":"10.1016\/j.bbrc.2022.08.010_bib13","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3390\/cancers14112613","article-title":"Early steps of resistance to targeted therapies in non-small-cell lung cancer","volume":"14","author":"Delahaye","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2022.08.010_bib14","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2022.08.010_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbapap.2009.12.010","article-title":"Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer","author":"Eck","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2022.08.010_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.08.010_bib17","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of Osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2022.08.010_bib18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers14081931","article-title":"Acquired mechanisms of resistance to osimertinib-the next challenge","volume":"14","author":"R\u00edos-Hoyo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2022.08.010_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.devcel.2015.03.002","article-title":"CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature","volume":"33","author":"Miller","year":"2015","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbrc.2022.08.010_bib20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2011.10.038","article-title":"The molecular basis for the endocytosis of small R-SNAREs by the clathrin adaptor CALM","volume":"147","author":"Miller","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2022.08.010_bib21","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1038\/s41467-020-17666-8","article-title":"Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V","volume":"11","author":"Rai","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2022.08.010_bib22","first-page":"100256","article-title":"Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation","volume":"15","author":"Rai","year":"2021","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.bbrc.2022.08.010_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ijc.20985","article-title":"Establishment of a human non-small cell lung cancer cell line resistant to gefitinib","volume":"116","author":"Koizumi","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2022.08.010_bib24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2022.08.010_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbrc.2022.08.010_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109441","article-title":"Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells","volume":"9","author":"Rai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2022.08.010_bib27","article-title":"New trend in ligand-induced EGFR trafficking: a dual-mode clathrin-mediated endocytosis model","volume":"255","author":"Zhou","year":"2022","journal-title":"J.\u00a0Proteonomics"},{"key":"10.1016\/j.bbrc.2022.08.010_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/mt.2009.281","article-title":"The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls","volume":"18","author":"Vercauteren","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2022.08.010_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","article-title":"EGF receptor trafficking: consequences for signaling and cancer","volume":"24","author":"Tomas","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bbrc.2022.08.010_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cam4.3635","article-title":"Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer","volume":"10","author":"Kim","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2022.08.010_bib31","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","article-title":"The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells","volume":"34","author":"Shin","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbrc.2022.08.010_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13046-021-02144-w","article-title":"Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response","volume":"40","author":"Matteoni","year":"2021","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.08.010_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114403","article-title":"Chlorpromazine, an antipsychotic agent, induces G2\/M phase arrest and apoptosis via regulation of the PI3K\/AKT\/mTOR-mediated autophagy pathways in human oral cancer","volume":"184","author":"Jhou","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2022.08.010_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105295","article-title":"Repurposing of antipsychotic trifluoperazine for treating brain metastasis, lung metastasis and bone metastasis of melanoma by disrupting autophagy flux","volume":"163","author":"Xia","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2022.08.010_bib35","doi-asserted-by":"crossref","first-page":"27580","DOI":"10.18632\/oncotarget.4768","article-title":"Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2022.08.010_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.665832","article-title":"Chlorpromazine sensitizes progestin-resistant endometrial cancer cells to MPA by upregulating PRB","volume":"11","author":"Cui","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2022.08.010_bib37","first-page":"418","article-title":"Chlorpromazine hydrochloride plays a tumor suppressive role in diffuse large B lymphoma by promoting the expression of S1PR2","volume":"39","author":"Liang","year":"2021","journal-title":"Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi"},{"key":"10.1016\/j.bbrc.2022.08.010_bib38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.18632\/oncotarget.28010","article-title":"Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment","volume":"12","author":"Kamgar-Dayhoff","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2022.08.010_bib39","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2217\/pgs.15.122","article-title":"PTEN and PI3K\/AKT in non-small-cell lung cancer","volume":"16","author":"Perez-Ramirez","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbrc.2022.08.010_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93815-3","article-title":"PTEN loss promotes oncogenic function of STMN1 via PI3K\/AKT pathway in lung cancer","volume":"11","author":"Xun","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22011159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22011159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:43:53Z","timestamp":1762094633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22011159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":40,"alternative-id":["S0006291X22011159"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.08.010","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}